NN

Novo Nordisk

Every trial this sponsor leads in the registry, and everything it has published.

1,150All trials
Recruiting60
Recruited31
Not yet recruiting13
By invitation13
Completed969
Stopped64

117 active · 10% of this sponsor’s registry footprint

Metabolic/Endocrine/Nutrition76 trials
Cardiovascular12 trials
Haematology11 trials
Gastroenterology & Hepatology5 trials
Renal & Urology4 trials
Oncology3 trials
Genetic & Rare Disease2 trials
Womens Health2 trials

Not shown above: 1 Phase 1 healthy-volunteer trial.

Trials by phase

Phase 1479
Phase 2116
Phase 3361
Phase 4104
Unphased90

Pipeline by phase · 40 drugs in active development

Phase 3 · 15 drugs

Amycretin (NNC0487-0111)13 trials · 10 recruitingest. Nov 2027
Cagrilintide11 trials · 6 recruitingest. Apr 2027
Zenagamtide4 trials · 1 recruitingest. Jun 2028
Concizumab3 trials
Etavopivat3 trials · 3 recruitingest. Aug 2027
Somapacitan3 trials
Ziltivekimab3 trials · 1 recruitingest. Oct 2026
Cagrisema2 trials · 1 recruitingest. Jun 2027

Phase 2 · 4 drugs

NNC0662-04194 trials · 3 recruitingest. Dec 2026
UBT2514 trials · 4 recruitingest. Jan 2027
CDR132L2 trials · 2 recruitingest. May 2027
NNC0519-01301 trial · 1 recruiting

Phase 1 · 18 drugs

NNC0537-14822 trials · 1 recruitingest. Jan 2027
Cagrilintide D1 trial · 1 recruitingest. May 2027
Coramitug1 trial · 1 recruitingest. May 2027
DCR-PDL11 trial · 1 recruiting
Glucose-dependent Insulinotropic Polypeptide (GIP)1 trial · 1 recruitingest. Jan 2027
INV-3471 trial · 1 recruitingest. Sept 2027
NNC0113-58401 trial · 1 recruitingest. Jan 2027

Phase 4 · 3 drugs

Semaglutide11 trials · 1 recruitingest. Oct 2026
Insulin icodec4 trials · 1 recruitingest. Jan 2027
Eptacog alfa (NovoSeven)1 trial · 1 recruitingest. Aug 2027

Not counted above: 1 unphased intervention.

Active trials only, code names and brands merged. 969 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 2 of 10 curated

Obesity (Metabolic & Nutrition)26 trials · 11 recruiting · 10 drugs2.4% of landscape
Type 2 diabetes (Endocrinology)18 trials · 8 recruiting · 12 drugs1.9% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon